At the World Without Disease Summit next month, Infinant Health CEO Mike Johnson will discuss his company’s unique insights into the infant microbiome.
Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi